AptaBio Therapeutics (Korea) Performance
| 293780 Stock | 6,520 210.00 3.12% |
The firm shows a Beta (market volatility) of -0.21, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning AptaBio Therapeutics are expected to decrease at a much lower rate. During the bear market, AptaBio Therapeutics is likely to outperform the market. At this point, AptaBio Therapeutics has a negative expected return of -0.61%. Please make sure to confirm AptaBio Therapeutics' total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if AptaBio Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days AptaBio Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Total Cashflows From Investing Activities | 1.1 B |
AptaBio |
AptaBio Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,005,000 in AptaBio Therapeutics on August 31, 2024 and sell it today you would lose (332,000) from holding AptaBio Therapeutics or give up 33.03% of portfolio value over 90 days. AptaBio Therapeutics is generating negative expected returns and assumes 3.9153% volatility on return distribution over the 90 days horizon. Simply put, 34% of stocks are less volatile than AptaBio, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
AptaBio Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AptaBio Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AptaBio Therapeutics, and traders can use it to determine the average amount a AptaBio Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.157
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 293780 |
Estimated Market Risk
| 3.92 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.61 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AptaBio Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AptaBio Therapeutics by adding AptaBio Therapeutics to a well-diversified portfolio.
AptaBio Therapeutics Fundamentals Growth
AptaBio Stock prices reflect investors' perceptions of the future prospects and financial health of AptaBio Therapeutics, and AptaBio Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AptaBio Stock performance.
| Return On Equity | -17.47 | |||
| Return On Asset | -0.0568 | |||
| Operating Margin | (17.13) % | |||
| Current Valuation | 794.49 B | |||
| Shares Outstanding | 10.88 M | |||
| Price To Sales | 926.14 X | |||
| Revenue | 223.68 M | |||
| EBITDA | (6.58 B) | |||
| Cash And Equivalents | 6.57 B | |||
| Total Debt | 46.77 M | |||
| Cash Flow From Operations | (8.9 B) | |||
| Total Asset | 64.91 B | |||
About AptaBio Therapeutics Performance
By analyzing AptaBio Therapeutics' fundamental ratios, stakeholders can gain valuable insights into AptaBio Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AptaBio Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AptaBio Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about AptaBio Therapeutics performance evaluation
Checking the ongoing alerts about AptaBio Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AptaBio Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AptaBio Therapeutics generated a negative expected return over the last 90 days | |
| AptaBio Therapeutics has high historical volatility and very poor performance | |
| The company reported the revenue of 223.68 M. Net Loss for the year was (10.69 B) with profit before overhead, payroll, taxes, and interest of 336.97 M. | |
| AptaBio Therapeutics has accumulated about 6.57 B in cash with (8.9 B) of positive cash flow from operations. | |
| Roughly 34.0% of the company shares are owned by insiders or employees |
- Analyzing AptaBio Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AptaBio Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining AptaBio Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AptaBio Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of AptaBio Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AptaBio Therapeutics' stock. These opinions can provide insight into AptaBio Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for AptaBio Stock analysis
When running AptaBio Therapeutics' price analysis, check to measure AptaBio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AptaBio Therapeutics is operating at the current time. Most of AptaBio Therapeutics' value examination focuses on studying past and present price action to predict the probability of AptaBio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AptaBio Therapeutics' price. Additionally, you may evaluate how the addition of AptaBio Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |